1. Scrip
  2. >>R&D
  3. >>Clinical Trials

EASL: Tirzepatide Is The One To Beat In MASH

 
• By Elizabeth Cairns

An important mid-stage trial succeeds, but an odd finding on the fibrosis endpoint will spur close examination of Lilly’s incretin.    

Winners
• Source: Alamy

Tirzepatide has already proven itself highly effective in diabetes and obesity; now it is starting to look like the best bet in metabolic dysfunction-associated steatohepatitis (MASH), too. Improvements in both MASH and liver fibrosis after a year’s treatment with Eli Lilly and Company’s GIP/GLP-1 agonist look competitive with the best MASH therapies on a cross-trial basis.

Key Takeaways
  • Phase II data coming at EASL position Lilly’s tirzepatide ahead of most other MASH therapies.
  • The company is evaluating the candidate’s path forward.
  • A Phase III trial...

Data from the keenly awaited SYNERGY-NASH trial are to be presented at the European Association for the Study of the Liver (EASL)’s annual meeting in Milan, Italy, on Saturday, but...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

ASCO: Carvykti Data Raise Possibility Of Myeloma Cure

 
• By Alaric DeArment

J&J presented data at the American Society of Clinical Oncology meeting showing more than five-year disease- and therapy-free survival, but a myeloma working group will need to define what makes a cure.

Vigil’s Iluzanebart Disappoints In Rare Neurodegenerative Disease

 
• By Jessica Merrill

The Phase II TREM2 agonist is not part of Sanofi’s planned acquisition.

Merus Raises $300m After ASCO Success

 
• By Andrew McConaghie

The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By Kevin Grogan

US green light will further expand sales of the prostate cancer blockbuster.

More from R&D

Degron Eyes Deals For Novel Molecular Glue Degrader Assets

 
• By Dexter Jie Yan

Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.

Kymera STAT6 Data Set The Bar For ‘Dupixent-In-A-Pill’ Race

 
• By Jessica Merrill

Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.

ASCO: Zepzelca Tecentriq Combo A Lung Cancer Success For Jazz and Roche

 
• By Andrew McConaghie

Small-cell lung cancer treatment is rapidly evolving, but Jazz and Roche are set to create a new maintenance therapy setting with their Zepzelca plus Tecentriq combination.